BMS gets FDA approval for Opdivo plus chemotherapy to treat resectable NSCLC
In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy showed superior outcomes compared to platinum-doublet chemotherapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Mar 22
In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy showed superior outcomes compared to platinum-doublet chemotherapy…
07 Mar 22
Discovered at Zydus Research Centre, Oxemia is a differentiated HIF-PH Inhibitor, the first alternative to injectable erythropoietin-stimulating agents…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 22
The new Enterprise Solutions Hub will support the US, Canada and Latin America, offering services similar to its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 22
In the Phase 3 MELODY trial, nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused…
03 Mar 22
Plant-based food is on the rise, with proven benefits for our health and the environment. But is this…
03 Mar 22
Adagene will conduct early-stage research to develop masked versions of Sanofi’s antibody candidates using its SAFEbody technology
03 Mar 22
The acquisition is expected to expand Aceto’s nutraceuticals capabilities and complements its footprint in the expanding life sciences…
02 Mar 22
The acquisition will expand AbbVie's neuroscience portfolio with Syndesi’s synaptic vesicle protein 2A (SV2A) modulators, including its lead…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Mar 22
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
01 Mar 22
Through the acquisition, Canon Medical aims to enhance its technology, development, and manufacturing of advanced digital imaging solutions…